A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr286, not Thr288

Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition

(2012) Jing Hu et al.   INTERNATIONAL JOURNAL OF CANCER

CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL

(2011) Rebecca Gilley et al.   CELLULAR SIGNALLING

BIMEL, an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation

(2011) C. M. Wiggins et al.   JOURNAL OF CELL SCIENCE

Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells

(2011) D. Z. Ewton et al.   MOLECULAR CANCER THERAPEUTICS

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells

(2010) Jingchun Gao et al.   CANCER BIOLOGY & THERAPY

Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species

(2009) X. Deng et al.   CANCER RESEARCH

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

(2009) Nora Göckler et al.   FEBS Journal

Mirk Regulates the Exit of Colon Cancer Cells from Quiescence

(2009) Kideok Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ERK1/2 and p38 cooperate to delay progression through G1 by promoting cyclin D1 protein turnover

(2008) Ruth M. Densham et al.   CELLULAR SIGNALLING